Search results for " cardiac dysfunction"

showing 2 items of 2 documents

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct

Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.

2016

Background: Chemotherapy cardiotoxicity is an emerging problem and it is very important to prevent cardiac dysfunction caused by anticancer drugs. The aim of this study was to assess the alterations of the cardiac function induced by chemotherapy in a follow-up of 2 years and to evaluate the cardioprotective role of angiotensin-converting enzyme inhibitors (ACEIs) in the prevention of cardiac dysfunction. Methods: A prospective study was carried out using patients with breast cancer (85 women; median age 57W12years) and other inclusion and exclusion criteria. On the basis of treatment, patients were divided into six groups: fluorouracil-epirubicincyclophosphamide, FEC (group A); FEC and tra…

Cardiac function curveAdultmedicine.medical_specialtyCardiotonic Agentsmedicine.medical_treatmentAngiotensin-Converting Enzyme InhibitorsBreast Neoplasms030204 cardiovascular system & hematologyBioinformaticsCardiac dysfunctionAngiotensin-converting enzyme inhibitor; Cardiotoxicity; Chemotherapy; Prevention; Tissue Doppler imaging; Adult; Aged; Aged 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Early Diagnosis; Echocardiography Doppler; Female; Follow-Up Studies; Humans; Middle Aged; Prospective Studies03 medical and health sciencesTissue Doppler imaging0302 clinical medicinecardiac toxicity anti cancer drugs cardiac dysfunctionInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overMedicineChemotherapyHumansProspective StudiesAgedAged 80 and overCardiotoxicityChemotherapybusiness.industryPreventionFollow up studiesDopplerGeneral MedicineMiddle AgedCardiotoxicityEchocardiography DopplerClinical trialEarly DiagnosisAngiotensin-converting enzyme inhibitorEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct